Use of random versus apheresis platelet concentrates

Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components

“…To date, there is little evidence to suggest that this phenomenon is clinically meaningful, as prolonged platelet storage has not been shown to increase mixed lymphocyte reactions and concentration of cytokines in PSPP . Additionally, since PSPP are derived from up to four to six different donors, they have a greater antigen/epitope diversity . This factor may increase the probability of enhanced antigenic immunogenicity.…”

“…Buffy‐coat‐derived pooled platelets have been reported to have significantly lower ATR rates than SDP regardless of the presence or absence of additive solution with ATR rates of 0·156% vs. 0·595%, respectively . In the presence of additive solutions, the ATR rate was significantly reduced to 0·024% and 0·312% in PSPP and SDP, respectively .…”

PAS‐G supports platelet reconstitution after cryopreservation in the absence of plasma

“…The use of PAS offers an alternative to plasma for the reconstitution of cryopreserved PLTs, with several benefits. First, PASs are well‐defined solutions of known composition and are not associated with transfusion reactions or increased donor exposure . Further, the use of PAS instead of plasma would enable PLTs to be available for transfusion more quickly than if the plasma needed to be thawed before PLT reconstitution.…”

“…However, reducing or replacing plasma with PLT additive solution (PAS) also has potential advantages. In particular, the use of PAS to prepare PLT components reduces donor exposure for the recipient; maximizes plasma collection for other uses, such as fractionation; and leads to greater product uniformity . Therefore, the ability of ASs to maintain PLT quality after cryopreservation, with minimal plasma carryover deserves further investigation.…”

Concentrados de plaquetas procedentes de sangre total (buffy coat) u obtenidos por aféresis; ¿qué producto emplear?

“…El grado de utilizació n de ambos tipos de productos es muy heterogé neo entre diferentes instituciones y estados. En países como Finlandia, Holanda y Dinamarca, los CP procedentes de combinaciones de plaquetas provenientes de sangre total (pooles de BC) suponen el 85-95% de las plaquetas transfundidas, mientras que en Francia casi el 90% de estas unidades provienen de afé resis de donante ú nico 4,5 . En Españ a, la situació n es intermedia; así, en el añ o 2009 algo má s del 20% de las dosis terapé uticas de plaquetas infundidas provenían de afé resis.…”